All Articles in: Boston Scientific
Boston Scientific/Dystonia Europe/European Parkinson’s Disease Association PartnershipFebruary 26, 2014
Dystonia Europe and the European Parkinson’s Disease Association have announced that they are collaborate with Boston Scientific Corporation to increase awareness, understanding of solutions and to take initiatives in the worldwide fight against Parkinson’s disease and dystonia, two areas of high unmet need.
CE Mark for Boston Scientific WallFlex™ Esophageal Stent for Refractory Benign Esophageal StricturesFebruary 17, 2014
Boston Scientific Corporation has received CE Mark approval for its WallFlex™ Esophageal Fully Covered Stent to treat refractory benign esophageal strictures.
Boston Scientific has received CE Mark approval of its X4 line of quadripolar cardiac resynchronization therapy defibrillator (CRT-D) systems and seen first implantations in Italy.
Panel’s Yes Vote Means FDA Will Find it Hard to Say No to Boston’s WATCHMAN™ LAA Closure DeviceDecember 12, 2013
Could the FDA be about to approve a permanently indwelling, percutaneously inserted Left Atrial Appendage closure device? It’s hard to see the agency going against the 13:1 vote in favour from its expert panel.
Boston Scientific Reports Impressive Pain Relief Results for Precision Spectra™ Spinal Cord StimulatorDecember 6, 2013
New retrospective data presented at NANS 2013 this week show highly significant reduction in pain and high trial therapy success rate of Boston Scientific’s Precision Spectra in the treatment of chronic pain
Boston Scientific has followed its July CE mark approval of the Promus Premier drug eluting stent, with a newly announced FDA approval. The company claims “next generation” status, based on enhancements in stent design and delivery system.
Last month we noted the CE mark approval of Boston Scientific’s Lotus™ transcatheter heart valve, which was indicated for use in aortic valve patients for whom conventional surgery was a high risk option. Now the first two commercial implants of the Lotus Valve have taken place in a German hospital.
Boston Scientific’s FDA cleared and CE mark approved new embolectomy catheter features a proprietary shaft design that the company says enables better control In hard-to-navigate Vessels.
All Eyes on Watchman FDA Panel Meeting in DecemberNovember 13, 2013
December 11th sees the FDA’s Circulatory System Devices Panel meet to discuss, make recommendations, and vote on information related to the premarket approval application regarding the Boston Scientific WATCHMAN Left Atrial Appendage Closure Technology.
Medtronic is trumpeting quite a landmark with the publication of a first head-to-head randomized controlled trial of “third-generation” durable-polymer drug-eluting stents for the treatment of coronary artery disease in an “all-comers” patient population. Resolute Integrity’s greater longitudinal strength doesn’t seem to play out in better target vessel failure stats.
CE Mark for Boston Scientific’s Lotus™ TAVI SystemOctober 28, 2013
Boston Scientific’s Lotus™ Transcatheter Aortic Valve Implant has gained CE Mark approval as a treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.
Boston Scientific Wins Tech Award, But Plans Restructure LayoffsOctober 24, 2013
Boston Scientific is never far from the news and this week is no exception as the company gains a prestigious award for its recently acquired subcutaneous ICD technology. At the same time news was released that its ongoing restructuring plans are likely to result in up to 1500 job losses.
Boston Scientific Corporation has completed enrollment in the EVOLVE II randomized, controlled clinical trial of its SYNERGY™Stent System. The safety and efficacy study will support U.S. FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
FDA Nod for Boston Scientific’s IntellaTip MiFi™ XP Ablation Catheter and Zurpaz™ 8.5F Steerable SheathAugust 21, 2013
Boston Scientific Corporation continues to expand its electrophysiology (EP) offerings with U.S. FDA approval of its IntellaTip MiFi™ XP catheter and 510(k) clearance of its Zurpaz™ 8.5F steerable sheath. The company says these products join its growing portfolio of next generation EP tools designed to redefine ablation technology.
Boston Scientific Completes Enrollment In SuperNOVA Trial Evaluating Innova™ Self-Expanding Stent SystemAugust 20, 2013
Boston Scientific has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial evaluating the long-term (12 month) safety and effectiveness of its Innova™ Self-expanding Stent System.
GSK, Boston and Covidien Keep Toes in Water as SetPoint Medical Secures $27 Million FinancingAugust 9, 2013
Biomedical technology company SetPoint Medical,developing neuromodulation therapies for inflammatory diseases, has secured $27 million in financing from its current investors along with new investors who’s names you might recognise.
<< Previous Articles